Blog
RSS FeedPosted by Michael Wonder on 18 Nov 2019
Biostatistics: a fundamental discipline at the core of modern health data science
28 October 2019 - The value of our health and medical research investment is at risk unless we foster the discipline ...
Posted by Michael Wonder on 09 Oct 2019
High health care costs suggest review is needed: report
8 October 2019 - The federal government’s annual $6 billion spend on the health insurance rebate could be redirected to ...
Posted by Michael Wonder on 08 Oct 2019
ICER identifies costliest US drug-price hikes that are not supported by new clinical evidence
8 October 2019 - In 2017 and 2018, out of nine identified drugs that had substantial price increases on top of ...
Posted by Michael Wonder on 03 Sep 2019
Bad diagnosis: health care system muddled, lacking leadership major report finds
3 September 2019 - The review is being led by former prime minister Helen Clark's chief of staff, Heather Simpson. ...
Posted by Michael Wonder on 28 Aug 2019
An international perspective on the paradoxes of US health care
28 August 2019 - Each year, the Commonwealth Fund selects an international cohort of Harkness Fellows in health care policy ...
Posted by Michael Wonder on 28 Aug 2019
Academics and researchers raise concerns with FDA’s plan for ‘integrated reviews’
28 August 2019 - More than 50 academics and researchers from Harvard, Yale, Johns Hopkins and other universities around the ...
Posted by Michael Wonder on 28 Aug 2019
Australian Public Assessment Reports for prescription medicines
28 August 2019 - TGA is reviewing the operation of transparency measures and are considering activities to increase transparency of ...
Posted by Michael Wonder on 28 Aug 2019
Patient Voice Aotearoa calls for PHARMAC reform
28 August 2019 - Patient Voice Aotearoa has launched a petition calling for the Minister of Health to initiate an ...
Posted by Michael Wonder on 21 Aug 2019
ICER Proposes Updates to 2020 Value Assessment Framework Methods and Procedures
21 August 2019 - Reflecting experience with current framework, benchmarking with other HTA groups, and public input, proposals include new emphasis ...
Posted by Michael Wonder on 07 Aug 2019
FDA should take additional steps to address factors that may affect approval rates in the first review cycle
7 August 2019 - Companies that make generic drugs—which have the same active ingredients as brand-name drugs—have to apply for ...
Posted by Michael Wonder on 30 Jul 2019
Reforms to the generic medicine market authorisation process
30 July 2019 - The TGA would like to thank respondents who provided submissions in response to the public consultation ...
Posted by Michael Wonder on 29 Jul 2019
FDA’s Sharpless outlines FDA's 4 top priorities: tech, hiring, modernisation and increased safety
24 July 2019 - Acting U.S. FDA Commissioner Ned Sharpless emailed agency staff yesterday outlining the FDA’s four main priorities. ...
Posted by Michael Wonder on 23 Jul 2019
U.S. District Court orders FDA to reconsider application for final approval of Brixadi (buprenorphine) extended release injection for the treatment of opioid use disorder
23 July 2019 - The U.S. District Court for the District of Columbia granted Braeburn’s motion for summary judgment, vacating ...
Posted by Michael Wonder on 22 Jul 2019
NICE numbers at 20
19 July 2019 - Leela Barham takes a look at NICE’s stats on technology appraisals to see how the agency ...
Posted by Michael Wonder on 22 Jul 2019
NICE announces details of health technology evaluation methods review
22 July 2019 - Following approval at its recent Board meeting NICE has confirmed the details of its review of the ...